CYP19A1 and pneumonitis: Use of these agents must be weighed against the increased risk of adverse events (e.g., neutropenia, pneumonitis)Endocrine therapies can be safely used (e.g., tamoxifen, aromatase inhibitors, fulvestrant) with no effect on immune functionFulvestrant needs monthly application